OverviewSuggest Edit

Horizon Therapeutics is a biopharmaceutical company building a pipeline and exploring potential uses for medicines. It offers medicines to treat rare, inflammation, and rheumatic diseases. In addition, the company provides patient advocacy, disease education as well as patient support and savings programs.

TypePublic
Founded2008
HQBallsbridge, IE
Websitehorizontherapeutics.com
Employee Ratings3.4
Overall CultureB-

Latest Updates

Employees (est.) (Dec 2019)1,200(+20%)
Job Openings64
Revenue (FY, 2020)$2.2 B(+70%)
Share Price (Mar 2021)$87.1 (+9%)
Cybersecurity ratingBMore

Key People/Management at Horizon Therapeutics

Brian K. Beeler

Brian K. Beeler

Executive Vice President, General Counsel
Geoffrey M. Curtis

Geoffrey M. Curtis

Executive Vice President, Corporate Affairs and Chief Communications Officer
Daniel A. Camardo

Daniel A. Camardo

Executive Vice President and President, U.S.
Paul W. Hoelscher

Paul W. Hoelscher

Executive Vice President, Chief Financial Officer
Michael Desjardin

Michael Desjardin

Executive Vice President, Technical Operations and Corporate Quality
Barry J. Moze

Barry J. Moze

Executive Vice President, Chief Administrative Officer
Show more

Horizon Therapeutics Office Locations

Horizon Therapeutics has offices in Ballsbridge, Chicago, Lake Forest, Novato and in 3 other locations
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Mannheim, DE
13 Joseph-Meyer-Straße
Chicago, IL, US
10 S Wacker Dr #2550
Lake Forest, IL, US
Landmark of Lake Forest 2, 150 S Saunders Rd
Novato, CA, US
3 Hamilton Landing #260Novato
South San Francisco, CA, US
1828, One, Tower Pl
Show all (7)

Horizon Therapeutics Financials and Metrics

Horizon Therapeutics Revenue

Embed Graph
View revenue for all periods
Horizon Therapeutics's revenue was reported to be $2.20 b in FY, 2020
USD

Revenue (FY, 2020)

2.2b

Gross profit (FY, 2020)

1.7b

Gross profit margin (FY, 2020), %

75.8%

Net income (FY, 2020)

389.8m

EBIT (FY, 2020)

490.0m

Market capitalization (30-Mar-2021)

19.5b

Closing stock price (30-Mar-2021)

87.1

Cash (31-Dec-2020)

2.1b

EV

18.5b
Horizon Therapeutics's current market capitalization is $19.5 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.1b1.2b1.3b2.2b

Revenue growth, %

14%8%

Cost of goods sold

546.3m422.3m362.2m532.7m

Gross profit

510.0m785.3m937.9m1.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

223.9m302.8m325.3m280.4m320.6m335.5m355.9m462.8m636.4m

Cost of goods sold

116.1m100.1m99.0m88.1m89.2m89.9m97.4m121.5m151.5m

Gross profit

107.8m202.8m226.3m192.2m231.5m245.5m258.5m341.3m485.0m

Gross profit Margin, %

48%67%70%69%72%73%73%74%76%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

751.4m958.7m1.1b2.1b

Accounts Receivable

367.4m464.7m408.7m659.7m

Prepaid Expenses

251.9m

Inventories

61.7m50.8m53.8m75.3m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

674.3m710.2m807.0m1.0b866.0m884.0m754.6m718.1m1.7b

Accounts Receivable

404.2m403.7m391.1m403.9m395.0m396.6m425.4m543.8m705.9m

Prepaid Expenses

220.3m

Inventories

47.4m50.1m53.1m51.6m51.0m58.5m68.2m66.1m77.1m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(410.5m)(74.2m)573.0m389.8m

Depreciation and Amortization

283.4m275.7m237.2m279.5m

Inventories

108.4m10.3m(3.3m)(21.5m)

Accounts Payable

(16.5m)(4.6m)(8.7m)16.0m
Quarterly
USDFY, 2017

Revenue/Employee

1.0m

Debt/Equity

1.6 x

Debt/Assets

0.4 x

Financial Leverage

4.2 x
Show all financial metrics

Horizon Therapeutics Operating Metrics

FY, 2017FY, 2018FY, 2019

Products

11 11 10

Pre-Clinical Phase Products

2 3 3

Phase I Trials Products

3 1

Phase III Trials Products

1 2 1
Show all operating metrics

Horizon Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Curzion Pharmaceuticals, Inc.April 01, 2020$45 m
River Vision Development Corp.May 08, 2017$150.30 m
Andromeda Biotech Limited
Horizon Medicines LLC
Horizon Ophthalmology, Inc
Horizon Orphan Holdings LLC
Horizon Orphan LLC
Horizon Pharma Aon Limited
Horizon Pharma Dó Limited
Horizon Pharma Israel Holding Corp. Ltd
Show more

Horizon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Horizon Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Horizon Therapeutics Online and Social Media Presence

Embed Graph

Horizon Therapeutics Company Culture

  • Overall Culture

    B-

    71/100

  • CEO Rating

    A

    80/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Horizon Therapeutics News and Updates

UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion

Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the first quarter. "Adding Viela's research and clinical development capabilities along with its deep, mid-st…

Thinking about buying stock in Sorrento Therapeutics, Aerpio Pharmaceuticals, Horizon Therapeutics, Riot Blockchain, or Royal Caribbean Cruises?

NEW YORK, Aug. 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, ARPO, HZNP, RIOT, and RCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Horizon Therapeutics halted for FDA advisory committee meeting on treatment for thyroid eye disease

Horizon Therapeutics Plc shares were halted in premarket trade Friday, ahead of a U.S. Food and Drug Administration advisory committee meeting to discuss a treatment for Thyroid Eye Disease, a serious autoimmune disorder. The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet at …

UPDATE: Horizon Pharma stock soars 17% premarket on positive trial of eye disease treatment

Horizon Pharma plc shares soared 17% in premarket trade Thursday, after the company announced positive results in a late-stage trial of a treatment for active thyroid eye disease, or TED. The company said the phase 3 trial of teprotumumab met its primary endpoint of improving proptosis, or bulging …

Horizon Therapeutics Blogs

Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer

Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer Content Import Wed, 08/28/2019 - 16:30 Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer 08/28/19 This release is a back…

American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)

DUBLIN --(BUSINESS WIRE)--Aug. 19, 2019-- A rigorous evaluation of the state of care for thyroid eye disease (TED) published in the American Journal of Ophthalmology (AJO) highlights the lack of current therapies to adequately treat the disease. The invited ‘Perspective’ discusses the potential for

Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

DUBLIN --(BUSINESS WIRE)--Aug. 19, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the company will participate in the following conference in September: Morgan Stanley 17 th Annual Global Healthcare Conference Date: Sept. 10, 2019 Presentation Time: 10 a.m.

Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community Website

-- New website features resources, transitions support and personal stories of people living with rare diseases -- DUBLIN --(BUSINESS WIRE)--Aug. 14, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of RAREisCommunity.com , a go-to resource for the more than 350 million

Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance

-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million ; Adjusted EBITDA of $124.1 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million ; KRYSTEXXA ® Second-Quarter 2019 Net Sales

Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program

Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program Content Import Thu, 08/01/2019 - 10:46 Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program 08/01/19 This release is a backfill from a News Wire General …
Show more

Horizon Therapeutics Frequently Asked Questions

  • When was Horizon Therapeutics founded?

    Horizon Therapeutics was founded in 2008.

  • Who are Horizon Therapeutics key executives?

    Horizon Therapeutics's key executives are Brian K. Beeler, Geoffrey M. Curtis and Daniel A. Camardo.

  • How many employees does Horizon Therapeutics have?

    Horizon Therapeutics has 1,200 employees.

  • What is Horizon Therapeutics revenue?

    Latest Horizon Therapeutics annual revenue is $2.2 b.

  • What is Horizon Therapeutics revenue per employee?

    Latest Horizon Therapeutics revenue per employee is $1.8 m.

  • Who are Horizon Therapeutics competitors?

    Competitors of Horizon Therapeutics include Aeglea, CSPC Pharmaceutical Group and Macleods Pharmaceuticals.

  • Where is Horizon Therapeutics headquarters?

    Horizon Therapeutics headquarters is located at Connaught House Burlington Rd, Ballsbridge.

  • Where are Horizon Therapeutics offices?

    Horizon Therapeutics has offices in Ballsbridge, Chicago, Lake Forest, Novato and in 3 other locations.

  • How many offices does Horizon Therapeutics have?

    Horizon Therapeutics has 7 offices.